Having worked in the equity industry for years I know there is...

Having worked in the equity industry for years I know there is pretty poor information on company announcements. Investors/participants rely on company and third party information and things fall through the cracks. For example, in the recent September 2019 investor presentation is included a 'key catalyst' section with forthcoming releases and dates:

CelGro® - Dental
Roll out European advocacy program: Ongoing
Australian market authorisation 1Q CY2020
US market authorisation 3Q CY2020

CelGro® - Tendon and Nerve
Nerve repair clinical data 3Q CY2020
CE Mark (EU) submission 4Q CY2019
TGA (AUS) submission 1Q CY2020


Ortho-ATI®
Investigation New Drug submission FDA 4Q CY2019
Complete J&J study recruitment 4Q CY2019

This is not actually an exhaustive list. You will also be getting, according to previous ASX announcements:

Further human nerve clinical trialresults in Q3 CY2019
A J&J ATI rotator-cuff clinical trail update in Q3 CY2019

Pre-clinical ACL reconstruction resultsin Q4 CY2019

Given these have been previously publicly advised dates, I felt vindicating in confirming these dates with the company and been assured they were accurate. I don't want to encourage any of you to buy the stock on this basis, but it may assuage many of you in light of the recent selling pressure (and the price spikes associated with recent positive clinical announcements). You still have two announcements in Q3 2019 (i.e. September) and hopefully three in Q4 2019. The update on the J&J ATI trial may prove price-sensitive if the wider market construes a potential partnership emerging given early results.